Condition

Islet Cell Tumor

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5

Recruiting0

Common interventions9

Lead sponsors shown5

Clinical trials

5 shown

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsNCT00454376 · 2006-10-01

UNKNOWN

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine TumorsNCT00227617 · 2005-06-08

TERMINATED

Thalidomide in Treating Patients With Metastatic Neuroendocrine TumorsNCT00027638 · 2001-03-01

COMPLETED

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNCT00006368 · 1998-01-01

COMPLETED

Indium In 111 Pentetreotide in Treating Patients With Refractory CancerNCT00002947 · 1996-10-01

TERMINATED

Common interventions

5-fluorouracilDRUG1 bevacizumabBIOLOGICAL1 indium In 111 pentetreotideRADIATION1 leucovorinDRUG1 oxaliplatinDRUG1 quality-of-life assessmentPROCEDURE1 questionnaire administrationOTHER1 thalidomideDRUG1 yttrium Y 90-edotreotideRADIATION1

Leading sponsors

Memorial Sloan Kettering Cancer Center 1 National Cancer Institute (NCI) 1 Novartis Pharmaceuticals 1 University of California, San Francisco 1 Yale University 1

Trial status mix

COMPLETED2

TERMINATED2

UNKNOWN1

Phase mix

PHASE12

PHASE22

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.